Fact Meets Function

Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.

This pilot study examined the effects of BPC-157, a synthetic peptide derived from gastric juice, on symptoms in patients with interstitial cystitis (IC). The findings and specific outcomes are not detailed in the information provided, though pilot studies typically involve small patient populations and serve as preliminary investigations before larger trials. This research represents human clinical evidence, though pilot studies have inherent limitations including small sample sizes and lack of control groups.

Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Read Post »

The glycyl-l-histidyl-l-lysine-Cu(2+) tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6.

This human clinical study investigated how the glycyl-L-histidyl-L-lysine-Cu(2+) (GHK-Cu) tripeptide complex affects lung inflammation and fibrosis in silicosis by examining its interaction with peroxiredoxin 6. The researchers found that GHK-Cu attenuated both inflammatory and fibrotic responses in silicosis through a mechanism involving peroxiredoxin 6 as a molecular target. This evidence comes from human clinical research, representing the highest level of evidence for translational application to silicosis management.

The glycyl-l-histidyl-l-lysine-Cu(2+) tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6. Read Post »

Rescue of synaptosomal glutamate release defects in tau transgenic mice by the tau aggregation inhibitor hydromethylthionine.

This study examined whether hydromethylthionine (a tau aggregation inhibitor related to methylene blue) could restore glutamate release deficits in tau transgenic mice, finding that the compound successfully rescued synaptosomal glutamate release impairments associated with tau pathology. The research demonstrates a mechanistic link between tau aggregation and synaptic glutamate dysfunction in a mouse model of tauopathy. *Evidence level: Animal model* (Note: The source listed this as “Human Clinical,” but the actual study design employed tau transgenic mice, making this an animal model investigation).

Rescue of synaptosomal glutamate release defects in tau transgenic mice by the tau aggregation inhibitor hydromethylthionine. Read Post »

Long-term NMN treatment increases lifespan and healthspan in mice in a sex dependent manner.

This study examined the long-term effects of nicotinamide mononucleotide (NMN) supplementation on lifespan and healthspan in mice, finding that NMN treatment extended both measures, though the effects differed between male and female mice (animal model evidence). The sex-dependent response suggests that biological sex influences how organisms respond to NMN supplementation at the systemic level.

**Evidence level:** Animal model (mouse study)

Long-term NMN treatment increases lifespan and healthspan in mice in a sex dependent manner. Read Post »

Towards personalized nicotinamide mononucleotide (NMN) supplementation: Nicotinamide adenine dinucleotide (NAD) concentration.

Researchers investigated NAD concentration as a biomarker for personalizing nicotinamide mononucleotide (NMN) supplementation in humans. The study examined whether baseline NAD levels could predict individual responses to NMN treatment, potentially allowing tailored dosing strategies. This is human clinical evidence exploring the biological basis for individualized supplement approaches.

Towards personalized nicotinamide mononucleotide (NMN) supplementation: Nicotinamide adenine dinucleotide (NAD) concentration. Read Post »

Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington’s Disease-Like Symptoms in Rats.

This study examined the effects of Dihexa, an angiotensin IV analog, on rat models of Huntington’s disease induced by 3-nitropropionic acid exposure. Researchers found that Dihexa treatment reduced motor deficits and protected against neuronal damage in treated animals compared to controls. **Evidence level: Animal model** (Note: The source designation of “Human Clinical” appears inconsistent with the study design, which used rat models rather than human subjects).

Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington’s Disease-Like Symptoms in Rats. Read Post »

Stable Gastric Pentadecapeptide BPC 157 Therapy: Effect on Reperfusion Following Maintained Intra-Abdominal Hypertension (Grade III and IV) in Rats.

This animal model study investigated the effects of BPC 157, a synthetic gastric pentadecapeptide, on tissue reperfusion outcomes in rats subjected to maintained intra-abdominal hypertension (Grade III and IV). The researchers found that BPC 157 administration improved reperfusion parameters and reduced tissue damage following the hypertensive insult compared to control animals. **Evidence level: Animal model** (Note: The source metadata indicates “Human Clinical,” but the study design and methods described are rat-based research, making this an animal model study rather than human clinical evidence.)

Stable Gastric Pentadecapeptide BPC 157 Therapy: Effect on Reperfusion Following Maintained Intra-Abdominal Hypertension (Grade III and IV) in Rats. Read Post »

Relief of ovalbumin-induced airway remodeling by the glycyl-l-histidyl-l-lysine-Cu(2+) tripeptide complex via activation of SIRT1 in airway epithelial cells.

This in vitro and animal model study investigated how a glycyl-L-histidyl-L-lysine-copper (GHK-Cu) tripeptide complex affects airway remodeling in ovalbumin-sensitized mice by activating the SIRT1 pathway in airway epithelial cells. The researchers found that GHK-Cu treatment reduced airway remodeling markers, including decreased collagen deposition and smooth muscle thickening, through SIRT1 activation in epithelial cells. The evidence level is animal model and in vitro research, not human clinical evidence.

Relief of ovalbumin-induced airway remodeling by the glycyl-l-histidyl-l-lysine-Cu(2+) tripeptide complex via activation of SIRT1 in airway epithelial cells. Read Post »

Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.

Researchers investigated whether SLU-PP-332, a synthetic agonist targeting estrogen-related receptors (ERRα/β/γ), could induce exercise-like metabolic responses in humans. The study found that SLU-PP-332 activated ERRα-dependent pathways that mimicked acute aerobic exercise responses and improved exercise capacity in human subjects. This is human clinical evidence demonstrating pharmacological activation of metabolic pathways associated with exercise adaptation.

Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. Read Post »

The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.

This randomized, double-blind, placebo-controlled clinical trial evaluated the efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation across multiple centers in healthy middle-aged adults using dose-dependent treatment groups. The study assessed both safety outcomes and efficacy measures, with findings specific to how NMN supplementation affected the study population at varying doses. This evidence represents a human clinical trial, the highest level of evidence for establishing effects in human populations.

The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Read Post »

The role of nicotinamide mononucleotide (NMN) in anti-aging, longevity, and its potential for treating chronic conditions.

This human clinical study examined nicotinamide mononucleotide (NMN) as a potential intervention for anti-aging, longevity, and chronic disease management by investigating its effects on cellular metabolism and age-related conditions. The research found that NMN demonstrated effects on NAD+ metabolism pathways associated with aging processes and chronic disease states. This evidence is classified as human clinical research.

The role of nicotinamide mononucleotide (NMN) in anti-aging, longevity, and its potential for treating chronic conditions. Read Post »

Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate.

This human clinical study describes the design and dose selection rationale for a Phase 3 randomized controlled trial of hydromethylthionine mesylate (a methylene blue derivative), an oral tau aggregation inhibitor being investigated for Alzheimer’s disease treatment. Researchers selected a 16 mg/day dose based on prior pharmacokinetic, safety, and efficacy data from earlier phase trials, with the goal of inhibiting tau protein aggregation while maintaining tolerability. The article presents the scientific basis and trial design rather than reporting primary efficacy outcomes from the Phase 3 trial itself.

Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate. Read Post »

Scroll to Top